Detailed Description:
This is a multiple-canter, open-label, phase II trial, 2-4 cycles treatment will be planned as neo-adjuvant therapy for NSCLC participants in stage II-IIIA.
Study design:
Participants: Newly diagnosed Resectable II-IIIA NSCLC without EGFR/ALK/ROS1/BRAF mutation.
TreatmentGroup Acamrelizumab 200 mg q3w i.v. for 2-4 cycles, apatinib 250mg pd po 3w/cycle for 2-4 cycles before surgery; Group Bcamrelizumab 200 mg q3w i.v. for 2-4 cycles, platinum-based chemotherapy q3w i.v for 2-4 cycles before surgery.
EndpointsPrimary objectives are to assess MPR and safety. Secondary objective is to assess 2-year overall survival (OS), disease-free survival (DFS), OS etc.
Exploratory end point is to explore biomarkers.
How understandable was the trial content above?
Hard to understand
Easy to understand
